DS
OBIO icon

David Shaw’s Orchestra BioMed OBIO Stock Holding History

David Shaw’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-938,388
Closed -$9.35M – 5423
2022
Q2 		$9.35M Buy
938,388
+51,487
+6% +$512K 0.01% 1451
2022
Q1 		$8.79M Buy
886,901
+108,119
+14% +$1.07M 0.01% 1719
2021
Q4 		$7.79M Buy
778,782
+526,264
+208% +$5.19M 0.01% 1917
2021
Q3 		$2.5M Buy
252,518
+222,717
+747% +$2.2M ﹤0.01% 2829
2021
Q2 		$304K Buy
+29,801
New +$308K ﹤0.01% 4272

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

David Shaw's OBIO Position: Q3 2022 in Review

David Shaw sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 938,388 shares — an estimated $9.35M sold.

David Shaw first reported a position in OBIO in Q2 2021 and held it in 5 quarters. The position peaked at $9.35M in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

  • David Shaw reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
  • David Shaw sold 938,388 Orchestra BioMed shares in Q3 2022, an estimated $9.35M.
  • David Shaw first reported a position in Orchestra BioMed in Q2 2021 and held it in 5 quarters.
  • David Shaw's Orchestra BioMed position peaked at $9.35M in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.